DE19806438A1 - Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung - Google Patents

Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung

Info

Publication number: DE19806438A1
Authority: DE; Germany
Prior art keywords: alkyl; alkoxy; phenyl; haloalkyl; alkylthio
Prior art date: 1998-02-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

DE19806438A

Other languages

German (de)

English (en)

Inventor

Wilhelm Amberg

Rolf Jansen

Andreas Kling

Dagmar Klinge

Hartmut Riechers

Stefan Hergenroeder

Manfred Raschack

Liliane Unger

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

BASF SE

Original Assignee

BASF SE

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-17

Filing date

1998-02-17

Publication date

1999-08-19

1998-02-17 Application filed by BASF SE filed Critical BASF SE

1998-02-17 Priority to DE19806438A priority Critical patent/DE19806438A1/de

1999-02-05 Priority to CA002321182A priority patent/CA2321182A1/en

1999-02-05 Priority to HR20000602A priority patent/HRP20000602A2/hr

1999-02-05 Priority to PL99342311A priority patent/PL342311A1/xx

1999-02-05 Priority to JP2000532405A priority patent/JP2002503726A/ja

1999-02-05 Priority to TR2000/02376T priority patent/TR200002376T2/xx

1999-02-05 Priority to PCT/EP1999/000776 priority patent/WO1999042453A1/de

1999-02-05 Priority to HU0100957A priority patent/HUP0100957A3/hu

1999-02-05 Priority to KR1020007008925A priority patent/KR20010086247A/ko

1999-02-05 Priority to CN99803037A priority patent/CN1291190A/zh

1999-02-05 Priority to BR9907911-9A priority patent/BR9907911A/pt

1999-02-05 Priority to EP99911657A priority patent/EP1066268A1/de

1999-02-05 Priority to IL13703899A priority patent/IL137038A0/xx

1999-02-05 Priority to AU30271/99A priority patent/AU3027199A/en

1999-02-05 Priority to SK1151-2000A priority patent/SK11512000A3/sk

1999-02-10 Priority to TW088102031A priority patent/TW579376B/zh

1999-02-16 Priority to ARP990100634A priority patent/AR014960A1/es

1999-02-16 Priority to ZA9901214A priority patent/ZA991214B/xx

1999-08-19 Publication of DE19806438A1 publication Critical patent/DE19806438A1/de

2000-07-04 Priority to BG104577A priority patent/BG104577A/bg

2000-08-15 Priority to NO20004075A priority patent/NO20004075D0/no

Status Withdrawn legal-status Critical Current

Links

229940118365 Endothelin receptor antagonist Drugs 0.000 title claims description 5
239000002308 endothelin receptor antagonist Substances 0.000 title claims description 5
208000006673 asthma Diseases 0.000 title claims description 4
208000037803 restenosis Diseases 0.000 title claims description 3
206010060862 Prostate cancer Diseases 0.000 title claims 2
208000000236 Prostatic Neoplasms Diseases 0.000 title claims 2
FJRJYJVRRLGFLN-UHFFFAOYSA-N 2-pyrimidin-2-yloxypropanoic acid Chemical class OC(=O)C(C)OC1=NC=CC=N1 FJRJYJVRRLGFLN-UHFFFAOYSA-N 0.000 title abstract 3
206010020772 Hypertension Diseases 0.000 title description 5
208000001647 Renal Insufficiency Diseases 0.000 title description 4
201000006370 kidney failure Diseases 0.000 title description 4
206010019280 Heart failures Diseases 0.000 title description 2
-1 methylene, ethylene, ethenylene Chemical group 0.000 claims abstract description 80
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 38
229910052717 sulfur Inorganic materials 0.000 claims abstract description 19
125000000217 alkyl group Chemical group 0.000 claims abstract description 16
125000001624 naphthyl group Chemical group 0.000 claims abstract description 13
229910052760 oxygen Inorganic materials 0.000 claims abstract description 12
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 11
125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 9
239000003112 inhibitor Substances 0.000 claims abstract description 9
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims abstract description 5
150000001768 cations Chemical class 0.000 claims abstract description 5
239000002876 beta blocker Substances 0.000 claims abstract description 4
229940097320 beta blocking agent Drugs 0.000 claims abstract description 4
239000002934 diuretic Substances 0.000 claims abstract description 4
229940030606 diuretics Drugs 0.000 claims abstract description 4
150000003839 salts Chemical class 0.000 claims abstract description 4
229940127291 Calcium channel antagonist Drugs 0.000 claims abstract 3
230000036454 renin-angiotensin system Effects 0.000 claims abstract 3
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 38
150000001875 compounds Chemical class 0.000 claims description 35
229910052736 halogen Inorganic materials 0.000 claims description 35
150000002367 halogens Chemical class 0.000 claims description 35
125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 26
108050009340 Endothelin Proteins 0.000 claims description 21
102000002045 Endothelin Human genes 0.000 claims description 21
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 21
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
125000005843 halogen group Chemical group 0.000 claims description 20
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 18
125000004093 cyano group Chemical group *C#N 0.000 claims description 14
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
239000001257 hydrogen Substances 0.000 claims description 13
229910052739 hydrogen Inorganic materials 0.000 claims description 13
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
239000011593 sulfur Substances 0.000 claims description 12
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 11
239000000126 substance Substances 0.000 claims description 11
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 10
150000002431 hydrogen Chemical class 0.000 claims description 10
125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
239000001301 oxygen Substances 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
125000004430 oxygen atom Chemical group O* 0.000 claims description 7
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
125000001424 substituent group Chemical group 0.000 claims description 6
125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 5
125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
201000010099 disease Diseases 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 4
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 4
229910052783 alkali metal Inorganic materials 0.000 claims description 4
150000001342 alkaline earth metals Chemical class 0.000 claims description 4
IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims description 4
125000004434 sulfur atom Chemical group 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
150000001340 alkali metals Chemical class 0.000 claims description 3
125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims description 3
FONOSWYYBCBQGN-UHFFFAOYSA-N ethylene dione Chemical group O=C=C=O FONOSWYYBCBQGN-UHFFFAOYSA-N 0.000 claims description 3
150000003536 tetrazoles Chemical class 0.000 claims description 3
229940123413 Angiotensin II antagonist Drugs 0.000 claims description 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
201000006474 Brain Ischemia Diseases 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
108090000790 Enzymes Proteins 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
230000001154 acute effect Effects 0.000 claims description 2
239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
206010008118 cerebral infarction Diseases 0.000 claims description 2
125000002883 imidazolyl group Chemical group 0.000 claims description 2
108090000623 proteins and genes Proteins 0.000 claims description 2
125000003226 pyrazolyl group Chemical group 0.000 claims description 2
125000000168 pyrrolyl group Chemical group 0.000 claims description 2
239000002461 renin inhibitor Substances 0.000 claims description 2
229940086526 renin-inhibitors Drugs 0.000 claims description 2
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
102000003729 Neprilysin Human genes 0.000 claims 2
108090000028 Neprilysin Proteins 0.000 claims 2
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 2
102000015427 Angiotensins Human genes 0.000 claims 1
108010064733 Angiotensins Proteins 0.000 claims 1
208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
239000008280 blood Substances 0.000 claims 1
210000004369 blood Anatomy 0.000 claims 1
239000000480 calcium channel blocker Substances 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
230000001684 chronic effect Effects 0.000 claims 1
210000003734 kidney Anatomy 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
229940124531 pharmaceutical excipient Drugs 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
230000002685 pulmonary effect Effects 0.000 claims 1
150000003852 triazoles Chemical class 0.000 claims 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract description 5
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract description 5
125000001188 haloalkyl group Chemical group 0.000 abstract description 4
239000003513 alkali Substances 0.000 abstract description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract description 2
125000003342 alkenyl group Chemical group 0.000 abstract 6
125000000304 alkynyl group Chemical group 0.000 abstract 6
125000001475 halogen functional group Chemical group 0.000 abstract 4
125000003545 alkoxy group Chemical group 0.000 abstract 3
125000004414 alkyl thio group Chemical group 0.000 abstract 2
125000004438 haloalkoxy group Chemical group 0.000 abstract 2
125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
125000000547 substituted alkyl group Chemical group 0.000 abstract 2
125000002757 morpholinyl group Chemical group 0.000 abstract 1
125000003831 tetrazolyl group Chemical group 0.000 abstract 1
150000003254 radicals Chemical class 0.000 description 26
238000012360 testing method Methods 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
239000000203 mixture Substances 0.000 description 13
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
230000027455 binding Effects 0.000 description 10
239000002585 base Substances 0.000 description 9
239000002904 solvent Substances 0.000 description 9
241001465754 Metazoa Species 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
230000036772 blood pressure Effects 0.000 description 5
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 5
230000000694 effects Effects 0.000 description 5
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
101800004490 Endothelin-1 Proteins 0.000 description 4
102100033902 Endothelin-1 Human genes 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
239000000872 buffer Substances 0.000 description 4
229940044551 receptor antagonist Drugs 0.000 description 4
239000002464 receptor antagonist Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
238000003820 Medium-pressure liquid chromatography Methods 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
150000005840 aryl radicals Chemical class 0.000 description 3
150000001735 carboxylic acids Chemical class 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
239000012528 membrane Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
125000000896 monocarboxylic acid group Chemical group 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
230000002792 vascular Effects 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
206010062575 Muscle contracture Diseases 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
HZZGDPLAJHVHSP-GKHTVLBPSA-N big endothelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CN=CN1 HZZGDPLAJHVHSP-GKHTVLBPSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
208000006111 contracture Diseases 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000005457 ice water Substances 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
208000001286 intracranial vasospasm Diseases 0.000 description 2
239000011630 iodine Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
SGRGRHADWKWHKZ-UHFFFAOYSA-N methyl 2-(5-fluoro-4,6-dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoate Chemical compound C=1C=CC=CC=1C(OC)(C=1C=CC=CC=1)C(C(=O)OC)OC1=NC(OC)=C(F)C(OC)=N1 SGRGRHADWKWHKZ-UHFFFAOYSA-N 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
125000003396 thiol group Chemical class [H]S* 0.000 description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
238000005303 weighing Methods 0.000 description 2
FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
125000004711 1,1-dimethylethylthio group Chemical group CC(C)(S*)C 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
VZAWCLCJGSBATP-UHFFFAOYSA-N 1-cycloundecyl-1,2-diazacycloundecane Chemical compound C1CCCCCCCCCC1N1NCCCCCCCCC1 VZAWCLCJGSBATP-UHFFFAOYSA-N 0.000 description 1
125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
SRXFXCKTIGELTI-UHFFFAOYSA-N 2-(4-chlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1 SRXFXCKTIGELTI-UHFFFAOYSA-N 0.000 description 1
YNDCDQGEBOJUHH-UHFFFAOYSA-N 2-(5-fluoro-4,6-dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid Chemical compound COC1=C(F)C(OC)=NC(OC(C(O)=O)C(OC)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 YNDCDQGEBOJUHH-UHFFFAOYSA-N 0.000 description 1
FQXMSHCCFXLEFK-UHFFFAOYSA-N 2-(5-fluoro-4-morpholin-4-ylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid Chemical compound O1CCN(CC1)C1=NC(=NC=C1F)OC(C(=O)O)C(C1=CC=CC=C1)(C1=CC=CC=C1)OC FQXMSHCCFXLEFK-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000004780 2-chloro-2,2-difluoroethyl group Chemical group [H]C([H])(*)C(F)(F)Cl 0.000 description 1
AGYUQBNABXVWMS-UHFFFAOYSA-N 2-chloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1 AGYUQBNABXVWMS-UHFFFAOYSA-N 0.000 description 1
125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
GCABHKYBDMLPOT-UHFFFAOYSA-N 5-fluoro-4,6-dimethoxy-2-methylsulfonylpyrimidine Chemical compound COC1=NC(S(C)(=O)=O)=NC(OC)=C1F GCABHKYBDMLPOT-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102000010180 Endothelin receptor Human genes 0.000 description 1
108050001739 Endothelin receptor Proteins 0.000 description 1
102100040611 Endothelin receptor type B Human genes 0.000 description 1
102400000686 Endothelin-1 Human genes 0.000 description 1
102100029110 Endothelin-2 Human genes 0.000 description 1
108090000387 Endothelin-2 Proteins 0.000 description 1
102100029109 Endothelin-3 Human genes 0.000 description 1
108010072844 Endothelin-3 Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
125000002723 alicyclic group Chemical group 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000005336 allyloxy group Chemical group 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960001301 amobarbital Drugs 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
125000004391 aryl sulfonyl group Chemical group 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
AXFHDDDNZLFQKF-UHFFFAOYSA-N benzyl 2-(5-fluoro-4-morpholin-4-ylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC)C(C(=O)OCC=1C=CC=CC=1)OC(N=1)=NC=C(F)C=1N1CCOCC1 AXFHDDDNZLFQKF-UHFFFAOYSA-N 0.000 description 1
LPYKDGZLQIPQQP-UHFFFAOYSA-N benzyl 2-hydroxy-3-methoxy-3,3-diphenylpropanoate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC)C(O)C(=O)OCC1=CC=CC=C1 LPYKDGZLQIPQQP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
229960003750 ethyl chloride Drugs 0.000 description 1
125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000002390 heteroarenes Chemical class 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
125000004464 hydroxyphenyl group Chemical group 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
BEPLSLADXOJCBY-UHFFFAOYSA-N methyl 2-hydroxy-3-methoxy-3,3-diphenylpropanoate Chemical compound C=1C=CC=CC=1C(OC)(C(O)C(=O)OC)C1=CC=CC=C1 BEPLSLADXOJCBY-UHFFFAOYSA-N 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
150000002902 organometallic compounds Chemical class 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
229910000105 potassium hydride Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000036316 preload Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000003380 propellant Substances 0.000 description 1
FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
208000002815 pulmonary hypertension Diseases 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000035939 shock Effects 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000005690 transetherification reaction Methods 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
230000006442 vascular tone Effects 0.000 description 1
239000002525 vasculotropin inhibitor Substances 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DE19806438A 1998-02-17 1998-02-17 Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung Withdrawn DE19806438A1 (de)

Priority Applications (20)

Application Number	Priority Date	Filing Date	Title
DE19806438A DE19806438A1 (de)	1998-02-17	1998-02-17	Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
CN99803037A CN1291190A (zh)	1998-02-17	1999-02-05	5-取代的嘧啶－2－基氧基羧酸衍生物及其制法和作为内皮肽拮抗剂的用途
IL13703899A IL137038A0 (en)	1998-02-17	1999-02-05	5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
PL99342311A PL342311A1 (en)	1998-02-17	1999-02-05	Novel derivatives of carboxylic acids containing pyrimidinic rings substituted at position 5, method of obtaining them and application of such derivatives
JP2000532405A JP2002503726A (ja)	1998-02-17	1999-02-05	５−置換ピリミジン−２−イルオキシカルボン酸誘導体、その製造およびそのエンドセリンアンタゴニストとしての使用
TR2000/02376T TR200002376T2 (tr)	1998-02-17	1999-02-05	5-İkameli pirimidin-2-iloksi karbon asidi türevleri/imalatları/endotelin-antagonistleri olarak kullanımları
PCT/EP1999/000776 WO1999042453A1 (de)	1998-02-17	1999-02-05	5-substituierte pyrimidin-2-yloxy-carbonsäurederivate, deren herstellung und deren verwendung als endothelin-antagonisten
HU0100957A HUP0100957A3 (en)	1998-02-17	1999-02-05	5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same, their use and pharmaceutical compositions containing them
KR1020007008925A KR20010086247A (ko)	1998-02-17	1999-02-05	5-치환 피리미딘-2-일옥시 카르복실산 유도체, 그의 제조및 엔도셀린 길항제로서의 그의 용도
CA002321182A CA2321182A1 (en)	1998-02-17	1999-02-05	5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
BR9907911-9A BR9907911A (pt)	1998-02-17	1999-02-05	Derivado de ácido carboxìlico, uso do mesmo, combinação, e, preparação de droga para administração oral, parenteral e intra-parenteral
EP99911657A EP1066268A1 (de)	1998-02-17	1999-02-05	5-substituierte pyrimidin-2-yloxy-carbonsäurederivate, deren herstellung und deren verwendung als endothelin-antagonisten
HR20000602A HRP20000602A2 (en)	1998-02-17	1999-02-05	5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
AU30271/99A AU3027199A (en)	1998-02-17	1999-02-05	5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
SK1151-2000A SK11512000A3 (sk)	1998-02-17	1999-02-05	5-substituované deriváty pyrimidín-2-yloxy karboxylových kyselín, ich príprava a ich využitie ako antagonistov endotelínu
TW088102031A TW579376B (en)	1998-02-17	1999-02-10	Novel carboxylic acid derivatives having a 5-substituted pyrimidine ring, their preparation and use
ARP990100634A AR014960A1 (es)	1998-02-17	1999-02-16	Derivados de acido carboxilico pirimidin 5-sustituido, su uso, combinaciones farmaceuticas que los comprenden y composiciones farmaceuticas que contienendichos derivados
ZA9901214A ZA991214B (en)	1998-02-17	1999-02-16	Novel carboxylic acid derivatives having a 5-substituted pyrimidine ring, their preparation and use.
BG104577A BG104577A (bg)	1998-02-17	2000-07-04	Производни на 5-заместени пиримидин-2-илокси-карбоксилни киселини, тяхното получаване и използване като ендотелин-антагонисти
NO20004075A NO20004075D0 (no)	1998-02-17	2000-08-15	Substituerte pyrimidin-2-yloksy-karboksylsyrederivater, fremstilling av disse og deres anvendelse som endotelin- antagonister

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19806438A DE19806438A1 (de)	1998-02-17	1998-02-17	Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung

Publications (1)

Publication Number	Publication Date
DE19806438A1 true DE19806438A1 (de)	1999-08-19

Family

ID=7857948

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE19806438A Withdrawn DE19806438A1 (de)	1998-02-17	1998-02-17	Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung

Country Status (20)

Country	Link
EP (1)	EP1066268A1 (no)
JP (1)	JP2002503726A (no)
KR (1)	KR20010086247A (no)
CN (1)	CN1291190A (no)
AR (1)	AR014960A1 (no)
AU (1)	AU3027199A (no)
BG (1)	BG104577A (no)
BR (1)	BR9907911A (no)
CA (1)	CA2321182A1 (no)
DE (1)	DE19806438A1 (no)
HR (1)	HRP20000602A2 (no)
HU (1)	HUP0100957A3 (no)
IL (1)	IL137038A0 (no)
NO (1)	NO20004075D0 (no)
PL (1)	PL342311A1 (no)
SK (1)	SK11512000A3 (no)
TR (1)	TR200002376T2 (no)
TW (1)	TW579376B (no)
WO (1)	WO1999042453A1 (no)
ZA (1)	ZA991214B (no)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000073276A3 (de) *	1999-06-01	2001-05-10	Basf Ag	Carbonsäurederivate mit arylsubstituierten stickstoffheterocyclen, ihre herstellung und verwendung als endothelin-rezeptor-antagonisten
RU2346703C2 (ru) *	2000-11-17	2009-02-20	Новартис Аг	Синергетические комбинации, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний
WO2009017777A3 (en) *	2007-07-31	2009-04-09	Gilead Colorado Inc	Metabolites and derivatives of ambrisentan

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE026195T2 (en) *	2008-01-22	2016-05-30	Dow Agrosciences Llc	4-Amino-5-fluoropyrimidine derivatives as fungicides
EP2647287A1 (en) *	2008-08-01	2013-10-09	Dow AgroSciences LLC	Use of 5-fluorocytosine and its derivatives as fungicides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4411225A1 (de) *	1994-03-31	1995-10-05	Basf Ag	Verwendung von Carbonsäurederivaten als Arzneimittel
DE19533023B4 (de) *	1994-10-14	2007-05-16	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) *	1996-04-12	1997-10-16	Basf Ag	Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) *	1996-04-12	1997-10-16	Basf Ag	Neue Carbonsäurederivate, ihre Herstellung und Verwendung
KR20000057642A (ko) *	1996-12-18	2000-09-25	스타르크, 카르크	헤테로시클릭 카르복실산 유도체, 그의 제제 및 엔도텔린 수용체길항제로서의 용도
DE19726146A1 (de) *	1997-06-19	1998-12-24	Basf Ag	Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
NZ504316A (en) *	1997-10-31	2002-12-20	Basf Ag	Pyrimidine substituted carboxylic acid derivatives which have amido side-chains useful as endothelin receptor antagonists

1998
- 1998-02-17 DE DE19806438A patent/DE19806438A1/de not_active Withdrawn
1999
- 1999-02-05 TR TR2000/02376T patent/TR200002376T2/xx unknown
- 1999-02-05 CN CN99803037A patent/CN1291190A/zh active Pending
- 1999-02-05 EP EP99911657A patent/EP1066268A1/de not_active Withdrawn
- 1999-02-05 WO PCT/EP1999/000776 patent/WO1999042453A1/de not_active Ceased
- 1999-02-05 PL PL99342311A patent/PL342311A1/xx unknown
- 1999-02-05 CA CA002321182A patent/CA2321182A1/en not_active Abandoned
- 1999-02-05 SK SK1151-2000A patent/SK11512000A3/sk unknown
- 1999-02-05 KR KR1020007008925A patent/KR20010086247A/ko not_active Withdrawn
- 1999-02-05 JP JP2000532405A patent/JP2002503726A/ja active Pending
- 1999-02-05 AU AU30271/99A patent/AU3027199A/en not_active Abandoned
- 1999-02-05 HR HR20000602A patent/HRP20000602A2/hr not_active Application Discontinuation
- 1999-02-05 HU HU0100957A patent/HUP0100957A3/hu unknown
- 1999-02-05 IL IL13703899A patent/IL137038A0/xx unknown
- 1999-02-05 BR BR9907911-9A patent/BR9907911A/pt not_active IP Right Cessation
- 1999-02-10 TW TW088102031A patent/TW579376B/zh active
- 1999-02-16 ZA ZA9901214A patent/ZA991214B/xx unknown
- 1999-02-16 AR ARP990100634A patent/AR014960A1/es not_active Application Discontinuation
2000
- 2000-07-04 BG BG104577A patent/BG104577A/bg unknown
- 2000-08-15 NO NO20004075A patent/NO20004075D0/no not_active Application Discontinuation

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000073276A3 (de) *	1999-06-01	2001-05-10	Basf Ag	Carbonsäurederivate mit arylsubstituierten stickstoffheterocyclen, ihre herstellung und verwendung als endothelin-rezeptor-antagonisten
RU2346703C2 (ru) *	2000-11-17	2009-02-20	Новартис Аг	Синергетические комбинации, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний
WO2009017777A3 (en) *	2007-07-31	2009-04-09	Gilead Colorado Inc	Metabolites and derivatives of ambrisentan
US8217155B2 (en)	2007-07-31	2012-07-10	Gilead Colorado, Inc.	Metabolites and derivatives of ambrisentan

Also Published As

Publication number	Publication date
CN1291190A (zh)	2001-04-11
AR014960A1 (es)	2001-04-11
HUP0100957A2 (hu)	2002-02-28
TW579376B (en)	2004-03-11
BG104577A (bg)	2001-03-30
NO20004075L (no)	2000-08-15
NO20004075D0 (no)	2000-08-15
HRP20000602A2 (en)	2001-06-30
ZA991214B (en)	2000-08-16
SK11512000A3 (sk)	2001-04-09
PL342311A1 (en)	2001-06-04
KR20010086247A (ko)	2001-09-10
WO1999042453A1 (de)	1999-08-26
AU3027199A (en)	1999-09-06
JP2002503726A (ja)	2002-02-05
EP1066268A1 (de)	2001-01-10
BR9907911A (pt)	2000-10-24
TR200002376T2 (tr)	2000-12-21
HUP0100957A3 (en)	2002-03-28
CA2321182A1 (en)	1999-08-26
IL137038A0 (en)	2001-06-14

Publication	Publication Date	Title
DE19636046A1 (de)	1998-03-12	Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
WO1999023078A2 (de)	1999-05-14	Neue carbonsäurederivate, die amidseitenketten tragen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
DE19614542A1 (de)	1997-10-16	Neue Carbonsäurederivate, ihre Herstellung und Verwendung
EP0946524A1 (de)	1999-10-06	Heterozyklische carbonsäurederivate, ihre herstellung und verwendung als endothelinrezeptorantagonisten
DE19726146A1 (de)	1998-12-24	Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19806438A1 (de)	1999-08-19	Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
EP1009741A1 (de)	2000-06-21	Neue carbonsäurederivate, ihre herstellung und verwendung als gemischte et a?/et b?-endothelin-rezeptorantagonisten
DE19750529A1 (de)	1999-05-20	Neue heterocyclisch substituierte alpha-Hydroxycarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19933164A1 (de)	2001-01-25	Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
DE19858779A1 (de)	2000-06-21	Neue ß-Amido und ß-Sulfonamidocarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19924892A1 (de)	2000-12-07	Neue Carbonsäurederivate mit arylsubstituierten Stickstoffheterocyclen, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
DE19809144A1 (de)	1999-09-09	Neue unsymmetrisch substituierte Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶LAMBDA¶/ET¶B¶-Rezeptorantagonisten
DE19836044A1 (de)	2000-02-17	Neue Carbonsäurederivate, die Ketoseitenketten tragen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten
DE19752904A1 (de)	1999-07-15	Neue Carbonsäurederivate, die Amidseitenketten tragen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten
DE19700884A1 (de)	1998-07-16	Heterozyklische Carbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19652763A1 (de)	1998-06-25	Heterozyklische Carbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19738578A1 (de)	1999-03-11	Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
DE10004052A1 (de)	2001-08-02	Neue Carbonsäurederivate mit alkylsubstituierten Triazinen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten
DE10025728A1 (de)	2001-11-29	Neue Carbamate und Harnstoffe, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten
DE19811915A1 (de)	1999-09-23	Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
DE19809376A1 (de)	1999-09-09	Neue Carbonsäurederivate, die Amidseitenketten tragen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten
WO2002064573A1 (de)	2002-08-22	Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten

Legal Events

Date	Code	Title	Description
2000-05-31	8130	Withdrawal